Literature DB >> 11206194

Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status.

S P Yap1, K H Yuen, J W Wong.   

Abstract

We have investigated the pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under fed and fasted conditions in eight healthy volunteers. The volunteers were administered a single oral dose of mixed tocotrienols (300 mg) under fed or fasted conditions. The bioavailability of tocotrienols under the two conditions was compared using the parameters peak plasma concentration (Cmax), time to reach peak plasma concentration (Tmax) and total area under the plasma concentration-time curve (AUC(o-infinity)). A statistically significant difference was observed between the fed and fasted logarithmic transformed values of Cmax (P < 0.01) and AUC(0-infinity) (P < 0.01) for all three tocotrienols. In addition, the 90% confidence intervals for the ratio of the logarithmic transformed AUC(0-infinity) values of alpha-, gamma- and delta-tocotrienols under the fed state over those of the fasted state were found to lie between 2.24-3.40, 2.05-4.09 and 1.59-3.81, respectively, while those of the Cmax were between 2.28-4.39, 2.31-5.87 and 1.52-4.05, respectively. However, no statistically significant difference was observed between the fed and fasted Tmax values of the three homologues. The mean apparent elimination half-life (t(1/2)) of alpha-, gamma- and delta-tocotrienols was estimated to be 4.4, 4.3 and 2.3 h, respectively, being between 4.5- to 8.7-fold shorter than that reported for alpha-tocopherol. No statistically significant difference was observed between the fed and fasted t(1/2) values. The mean apparent volume of distribution (Vd/f) values under the fed state were significantly smaller than those of the fasted state, which could be attributed to increased absorption of the tocotrienols in the fed state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206194     DOI: 10.1211/0022357011775208

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  60 in total

1.  Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  J Bioanal Biomed       Date:  2011-01-10

2.  Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability.

Authors:  Bilal S Abuasal; Courtney Lucas; Breanne Peyton; Alaadin Alayoubi; Sami Nazzal; Paul W Sylvester; Amal Kaddoumi
Journal:  Lipids       Date:  2012-01-24       Impact factor: 1.880

Review 3.  Utilization of Vitamin E Analogs to Protect Normal Tissues While Enhancing Antitumor Effects.

Authors:  Nukhet Aykin-Burns; Rupak Pathak; Marjan Boerma; Thomas Kim; Martin Hauer-Jensen
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

4.  Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production.

Authors:  Xingui Liu; Zhengya Gao; Qiang Fu; Lin Song; Peiyi Zhang; Xuan Zhang; Howard Hendrickson; Peter A Crooks; Daohong Zhou; Guangrong Zheng
Journal:  Bioorg Med Chem       Date:  2020-04-08       Impact factor: 3.641

5.  Acute effects of a single dose of tocotrienols on insulinemic and inflammatory responses in metabolic syndrome subjects after a high-fat challenge.

Authors:  H-L Che; M S Kanthimathi; R Loganathan; K H Yuen; A T B Tan; K R Selvaduray; K Nesaretnam; K-T Teng
Journal:  Eur J Clin Nutr       Date:  2016-10-19       Impact factor: 4.016

Review 6.  Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress.

Authors:  Edzard Schwedhelm; Renke Maas; Raphael Troost; Rainer H Böger
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Vitamin E delta-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration.

Authors:  Kazim Husain; Rony A Francois; Sean Z Hutchinson; Anthony M Neuger; Richard Lush; Domenico Coppola; Said Sebti; Mokenge P Malafa
Journal:  Pharmacology       Date:  2009-01-13       Impact factor: 2.547

8.  Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  Biomed Pharmacother       Date:  2009-11-14       Impact factor: 6.529

9.  Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS).

Authors:  Saeed Alqahtani; Alaadin Alayoubi; Sami Nazzal; Paul W Sylvester; Amal Kaddoumi
Journal:  Lipids       Date:  2014-06-17       Impact factor: 1.880

10.  Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.

Authors:  Sunitha V Bachawal; Vikram B Wali; Paul W Sylvester
Journal:  BMC Cancer       Date:  2010-03-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.